StemoniX to Present at Biotech Showcase 2020

December 19, 2019 - Co-Founder and Chief Executive Officer Ping Yeh presented at the Biotech Showcase 2020, January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco.

Emerald Bioscience Inc. Announces Cannabidiol-Valine-Hemisuccinate Possesses Enhanced Anti-Seizure Activity when Compared with Cannabidiol (CBD) in the StemoniX Human Neural Tissue Platform

December 10, 2019 - Data generated by StemoniX, Inc., using their proprietary microBrain 3D platform, demonstrated that the proprietary analog of CBD, cannabidiol-valine-hemisuccinate (CBDVHS) was both pharmacologically and therapeutically distinct from cannabidiol (CBD) when studied in an in vitro human neural tissue model mimicking chemically-induced seizure-like hyperactivity.

StemoniX and Atomwise Create Joint Venture Aligning microOrgan and AI Technologies for "Next Generation" Drug Discovery

December 3, 2019 -  StemoniX and Atomwise announce a joint venture that combines StemoniX's human microOrgan® platform with Atomwise's AI technology to enable the rapid discovery and development of novel small molecule therapies. The joint venture will initially target Rett syndrome, a rare neurodevelopmental disease.

StemoniX to Present at Piper Jaffray 31st Annual Healthcare Conference

November 21, 2019 - Chief Executive Officer Ping Yeh and Chief Financial Officer Andy LaFrence presented at the Piper Jaffray 31st Annual Healthcare Conference, December 3 – 5, 2019 at the Lotte New York Palace in New York.

StemoniX wins Most Disruptive new medical company at Singularity University’s Exponential Medicine Conference

November 7, 2019 - Chief Executive Officer Ping Yeh showed just how much StemoniX technology is "shaking up the markets" at the 2019 Singularity MEDy Awards winning the Most Disruptive New Medical Company!

The global computational biology market size is expected to reach USD 13.6 billion by 2024

October 28, 2019 - Computational Biology Market Size, Share & Trends Analysis Report By Application (Cellular & Biological Simulation, Drug Discovery & Disease Modelling), By Service, By End Use, And Segment Forecasts, 2019 - 2026

StemoniX Appoints Andrew D. C. LaFrence As Chief Financial Officer

October 16, 2019 - LaFrence Brings 35 Years Public and Private Company Experience to StemoniX

StemoniX's microBrain and microHeart Platforms to be Featured in Podium Presentation at the PREDiCT: 4th Annual 3D Tissue Models Summit

September 3, 2019 - StemoniX's Research and Development Director, Fabian Zanella, Ph.D., to present during the session "Physiologically-relevant 3D hiPSC-based platforms empowering drug discovery"

NIH taps StemoniX's organ-on-a-chip for opioid, addiction research

May 1, 2019 - The NIH’s National Center for Advancing Translational Sciences is teaming up with StemoniX to use its brain-on-a-chip platform to test new treatments for pain, opioid misuse and addiction. 

StemoniX Secures $14.4 Million to Accelerate Commercialization of microOrgan Drug Discovery Platforms

February 28, 2019 - Series B financing will drive expansion of commercial operations and development of new microOrgan platforms

2019

13300 67th Ave N,

Maple Grove, MN 55311, United States

(855) 783-6669

©2020 by StemoniX. All Rights Reserved.

StemoniX, microOrgan, microHeart, microBrain, microPancreas are registered trademarks of StemoniX, Inc.

  • LinkedIn
  • Twitter